Scarica l'app Stockscreener
16.79
1.63%
0.27
Dopo l'orario di chiusura:
16.79
Precedente Chiudi:
$16.52
Aprire:
$16.71
Volume 24 ore:
872.82K
Relative Volume:
0.77
Capitalizzazione di mercato:
$1.20B
Reddito:
$133.62M
Utile/perdita netta:
$-177.37M
Rapporto P/E:
-5.8097
EPS:
-2.89
Flusso di cassa netto:
$23.50M
1 W Prestazione:
-5.03%
1M Prestazione:
+12.46%
6M Prestazione:
+82.70%
1 anno Prestazione:
-30.13%
Intervallo 1D:
$16.45
$17.18
Intervallo di 1 settimana:
$16.43
$17.98
Portata 52W:
$6.92
$25.54
Xencor Inc Stock (XNCR) Company Profile
Nome
Xencor Inc
Settore
Industria
Telefono
626-305-5900
Indirizzo
465 N. HALSTEAD ST., PASADENA, CA
Confronta XNCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
16.79 | 1.18B | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-10-29 | Aggiornamento | Barclays | Underweight → Overweight |
| 2025-09-17 | Ripresa | Barclays | Underweight |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-04-21 | Iniziato | William Blair | Outperform |
| 2024-12-12 | Iniziato | Wells Fargo | Overweight |
| 2024-12-02 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Reiterato | BTIG Research | Buy |
| 2024-02-28 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Iniziato | BofA Securities | Buy |
| 2022-12-06 | Iniziato | Cowen | Outperform |
| 2022-10-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-21 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-02-24 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2020-02-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-01-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-08-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-04-12 | Iniziato | Guggenheim | Buy |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2017-03-02 | Iniziato | Instinet | Neutral |
| 2017-03-02 | Reiterato | Wedbush | Outperform |
| 2016-10-04 | Iniziato | Piper Jaffray | Overweight |
| 2015-12-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-08-05 | Reiterato | MLV & Co | Buy |
| 2015-02-12 | Reiterato | Oppenheimer | Outperform |
| 2015-01-28 | Reiterato | MLV & Co | Buy |
| 2014-07-11 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Xencor Inc Borsa (XNCR) Ultime notizie
Fundamentals Check: Why Xencor Inc XE9 stock signals breakout potential - moha.gov.vn
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies - BioSpace
Xencor (XNCR) Is Up 7.1% After Ultomiris Royalty Patent ExtensionWhat's Changed - simplywall.st
248,706 Shares in Xencor, Inc. $XNCR Acquired by Walleye Capital LLC - MarketBeat
Xencor Granted US Patent Extension of Certain Xtend Antibodies, Expects Additional Royalty Revenue - marketscreener.com
Xencor issued U.S. patent for Xtend Fc domain - TipRanks
Xencor extends Ultomiris royalty term to 2028 with new patent - Investing.com
Xencor extends Ultomiris royalty term to 2028 with new patent By Investing.com - Investing.com South Africa
Xencor Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Pullback Watch: What momentum indicators show for Xencor Inc stock2025 Sector Review & Smart Swing Trading Alerts - moha.gov.vn
Is Xencor Stock Built to Withstand a Pullback? - Trefis
How Xencor Inc. stock performs in interest rate cycles2025 Geopolitical Influence & Detailed Earnings Play Alerts - Newser
Xencor, Inc. $XNCR Shares Acquired by Panagora Asset Management Inc. - MarketBeat
What hedge fund moves indicate for Xencor Inc. (XE9) stockWeekly Earnings Recap & Low Drawdown Investment Strategies - Newser
What momentum indicators show for Xencor Inc. stock2025 Price Action Summary & High Conviction Investment Ideas - Newser
Its Stock Has Paid Off Big Time For Xencor Inc - setenews.com
Is Xencor Inc. stock a defensive play in 2025Quarterly Profit Review & Daily Growth Stock Investment Tips - Newser
Xencor (XNCR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Xencor Inc. diskutieren - sharewise.com
How supply shortages influence Xencor Inc. (XE9) stockJuly 2025 Opening Moves & Safe Capital Investment Plans - BỘ NỘI VỤ
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Rhenman & Partners Asset Management AB Has $1.30 Million Stake in Xencor, Inc. $XNCR - MarketBeat
Will Xencor Inc. (XE9) stock remain on Wall Street radarJuly 2025 Sector Moves & Real-Time Volume Triggers - BỘ NỘI VỤ
Truist Financial Initiates a Buy Rating on Xencor (XNCR) - The Globe and Mail
Xencor (NASDAQ:XNCR) Coverage Initiated by Analysts at Truist Financial - MarketBeat
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 27% Share Price Rise - simplywall.st
DCF Advisers LLC Cuts Stake in Xencor, Inc. $XNCR - MarketBeat
Xencor Shares Surge on Clinical Breakthroughs and Analyst Confidence - Ad-hoc-news.de
Truist Securities Initiates Coverage of Xencor (XNCR) with Buy Recommendation - MSN
Truist Securities initiates coverage on Xencor stock with Buy rating By Investing.com - Investing.com Canada
Truist Securities Initiates Coverage on Xencor (XNCR) with Buy R - GuruFocus
Truist Securities initiates coverage on Xencor stock with Buy rating - Investing.com India
Xencor’s XmAb819 Study: A Promising Step in Cancer Treatment - MSN
Primecap Management Co. CA Has $82.75 Million Holdings in Xencor, Inc. $XNCR - MarketBeat
Is Xencor Inc. stock a safe buy before earningsJuly 2025 Reactions & Free High Accuracy Swing Entry Alerts - newser.com
Will Xencor Inc. (XE9) stock benefit from commodity supercycleJuly 2025 Outlook & Weekly Setup with High ROI Potential - newser.com
Xencor Shares Show Renewed Promise as Biotech Specialist Stages Recovery - Ad-hoc-news.de
Bank of Montreal Can Boosts Holdings in Xencor, Inc. $XNCR - MarketBeat
Xencor Inc (XE9.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Xencor Inc. (XE9) stock undervalued by metricsWeekly Loss Report & Free Long-Term Investment Growth Plans - newser.com
Xencor upgraded to Overweight from Underweight at Barclays - MSN
Will Xencor Inc. (XE9) stock hit Wall Street targetsWatch List & Long Hold Capital Preservation Plans - newser.com
Xencor Inc Azioni (XNCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):